8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported) March 16, 2016
 ___________________________________

EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
___________________________________
 
 
 
 
 
Delaware
 
1-15525
 
36-4316614
(State or other jurisdiction
of incorporation)
 
(Commission
file number)
 
(IRS Employer
Identification No.)
 
 
 
 
One Edwards Way, Irvine, California
 
92614
(Address of principal executive offices)
 
(Zip Code)
 
(949) 250-2500
Registrant’s telephone number, including area code
 
N/A
(Former Name or Former Address, if Changed Since Last Report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
¨
Pre-Commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
¨
Pre-Commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






 
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2016, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Steven R. Loranger was appointed to the Company’s Board of Directors. The appointment was effective on March 16, 2016.

There is no arrangement or understanding between Mr. Loranger and any other persons pursuant to which he was selected as a director. Mr. Loranger has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.  Mr. Loranger will receive the same compensation and agreements as the Company’s other nonemployee directors as described in the Company’s 2015 Proxy Statement.

A copy of the press release announcing his appointment is filed as Exhibit 99.1.

 


Item 9.01    Financial Statements and Exhibits.

(d) Exhibits
99.1
Press Release dated March 17, 2016








SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 17, 2016
 
 
 
 
 
 
 
 
EDWARDS LIFESCIENCES CORPORATION
 
 
 
 
 
 
 
By:
/s/ Denise E. Botticelli
 
 
 
 
 
Denise E. Botticelli
 
 
Vice President, Associate General Counsel, and Secretary






EXHIBIT INDEX
 
 
 
 
 
Exhibit
Number
 
Description
99.1
 
Press Release dated March 17, 2016